• Contract executed with GlaxoSmithKline (GSK) to supply 4DMedical's functional lung imaging analytics
• CT:VQ receives UKCA certification for clinical use in the UK, expanding 4DMedical's European footprint
• 4DMedical included in the S&P/ASX 200 Index, reflecting significant progress over the past 12 months

4DMedical Limited (ASX:4DX), a global leader in respiratory imaging technology, has announced a series of commercial, regulatory and corporate milestones that further expand its global market access and validate the demand for its advanced cardiopulmonary imaging analytics platform. The company has entered a contract with GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies, to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. Additionally, 4DMedical's CT:VQ solution has received UKCA certification for clinical use in the United Kingdom, allowing for immediate commercial deployment across public and private healthcare providers. This regulatory clearance, combined with the existing CE Mark certification, positions 4DMedical to engage directly with leading European and UK clinicians, support investigator-initiated research, and contribute to the global clinical evidence base. Furthermore, 4DMedical has been included in the S&P/ASX 200 Index, reflecting the significant progress achieved over the past twelve months, including FDA clearance of CT:VQ, deployment at six leading U.S. academic medical centers, and growing pharmaceutical engagement with companies like AstraZeneca and now GSK.